Adocia (ADOC) - Total Assets
Based on the latest financial reports, Adocia (ADOC) holds total assets worth €28.45 Million EUR (≈ $33.27 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ADOC cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Adocia - Total Assets Trend (2008–2025)
This chart illustrates how Adocia's total assets have evolved over time, based on quarterly financial data. See what is Adocia's book value for net asset value and shareholders' equity analysis.
Adocia - Asset Composition Analysis
Current Asset Composition (December 2025)
Adocia's total assets of €28.45 Million consist of 83.9% current assets and 16.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 60.6% |
| Accounts Receivable | €5.48 Million | 19.3% |
| Inventory | €362.00K | 1.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Adocia's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ADOC market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Adocia's current assets represent 83.9% of total assets in 2025, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 60.6% of total assets in 2025, down from 74.4% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 19.3% of total assets.
Adocia Competitors by Total Assets
Key competitors of Adocia based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Adocia - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.19 | 1.08 | 3.40 |
| Quick Ratio | 1.17 | 1.07 | 3.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.84 Million | €1.60 Million | €25.72 Million |
Adocia - Advanced Valuation Insights
This section examines the relationship between Adocia's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 62.80 |
| Latest Market Cap to Assets Ratio | 3.18 |
| Asset Growth Rate (YoY) | 5.3% |
| Total Assets | €28.45 Million |
| Market Capitalization | $90.58 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Adocia's assets at a significant premium (3.18x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Adocia's assets grew by 5.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Adocia (2008–2025)
The table below shows the annual total assets of Adocia from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €28.45 Million ≈ $33.27 Million |
+5.31% |
| 2024-12-31 | €27.02 Million ≈ $31.59 Million |
+8.27% |
| 2023-12-31 | €24.96 Million ≈ $29.18 Million |
-18.48% |
| 2022-12-31 | €30.61 Million ≈ $35.79 Million |
+1.86% |
| 2021-12-31 | €30.05 Million ≈ $35.14 Million |
-33.46% |
| 2020-12-31 | €45.17 Million ≈ $52.80 Million |
-27.10% |
| 2019-12-31 | €61.95 Million ≈ $72.43 Million |
-11.55% |
| 2018-12-31 | €70.04 Million ≈ $81.89 Million |
+30.29% |
| 2017-12-31 | €53.76 Million ≈ $62.85 Million |
-31.77% |
| 2016-12-31 | €78.80 Million ≈ $92.12 Million |
-10.55% |
| 2015-12-31 | €88.09 Million ≈ $102.99 Million |
+67.66% |
| 2014-12-31 | €52.54 Million ≈ $61.43 Million |
+112.48% |
| 2013-12-31 | €24.73 Million ≈ $28.91 Million |
-32.48% |
| 2012-12-31 | €36.63 Million ≈ $42.82 Million |
+107.68% |
| 2011-12-31 | €17.64 Million ≈ $20.62 Million |
+17.08% |
| 2010-12-31 | €15.06 Million ≈ $17.61 Million |
-4.96% |
| 2009-12-31 | €15.85 Million ≈ $18.53 Million |
+63.32% |
| 2008-12-31 | €9.70 Million ≈ $11.34 Million |
-- |
About Adocia
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of act… Read more